Investigating a new treatment for uveal melanoma using a specific drug.
Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma
['FUNDING_SBIR_2'] · ONCOSPHERIX, INC. · NIH-10817841
This study is testing a new drug called 64B to see if it can help treat advanced eye cancer, specifically metastatic and high-risk uveal melanoma, by working alongside other treatments to slow down tumor growth and improve survival, making it a hopeful option for patients facing this condition.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ONCOSPHERIX, INC. (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-10817841 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new drug called 64B, which targets a specific protein involved in cancer growth, to treat metastatic and high-risk uveal melanoma, the most common eye cancer in adults. The approach involves using 64B in combination with other cancer therapies to enhance its effectiveness while minimizing side effects. The research includes preclinical studies in mice to evaluate how well 64B works in slowing tumor growth and improving survival rates. If successful, this treatment could offer a new option for patients with advanced uveal melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with metastatic or high-risk uveal melanoma.
Not a fit: Patients with early-stage uveal melanoma or those not diagnosed with this specific type of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and better-tolerated treatment option for patients with uveal melanoma.
How similar studies have performed: Previous studies have shown promising results with similar approaches, indicating potential for success in this novel treatment.
Where this research is happening
ATLANTA, UNITED STATES
- ONCOSPHERIX, INC. — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OFFERMANN, MARGARET KENNY — ONCOSPHERIX, INC.
- Study coordinator: OFFERMANN, MARGARET KENNY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer